FilingSEC EDGAR8-K
Cadrenal Therapeutics Reaches Agreement with FDA on Phase 3 Protocol for CAD-1005
· SEC accepted
StagePhase 3
Filing content
The company reached an agreement with the FDA on the primary endpoint and placebo control for the Phase 3 registrational study of CAD-1005 during a Type D meeting.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…